Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment

Completed · Phase 2

Conditions studied: Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma

In brief

The main purpose of this study was to assess the progression-free survival (PFS) based on local investigator assessment of pazopanib in participants with advanced and/or metastatic renal cell carcinoma (mRCC) following prior treatment with immune checkpoint inhibitors (ICI).

Key facts

Study ID
NCT03200717
Run by
Novartis Pharmaceuticals
People needed
62
Starts
2017-11-14
Expected to finish
2021-08-10
Last updated by the study team
2023-08-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.